Another Avastin biosimilar joins the party as Roche's grip on the market loosens

28 Sep 2022
endpts.com
Biosimilar
Avastin has attracted quite the crowd of biosimilars in recent years, and one more pharma company has elbowed its way in.
The label is notably missing hepatocellular carcinoma (HCC), which Avastin was approved to treat in combination with Tecentriq back in 2020.
Vegzelma is Celltrion’s third cancer biosimilar approved in the US. In the last two months, the drug had already won approval in the EU, UK and Japan. However, the drug is a bit late to the party, as a handful of Avastin biosimilars have gone to market in recent years, including Amgen’s Mvasi, Pfizer’s Zirabev, and Amneal Pharmaceuticals and mAbxience’s Alymsys.
Avastin sales have plummeted from $7 billion-plus heights since Amgen’s contender hit the market in 2019. Mvasi was approved in 2017, marking the first biosimilar cleared for the treatment of cancer in the US. Amgen rolled out the drug at a 15% discount from Avastin, charging $677.40 per 100 mg and $2,709.60 per 400 mg.
Chasing Roche's aging blockbuster franchise, Amgen/Allergan roll out Avastin, Herceptin knockoffs at discount
Last year, Avastin raked in a mere $3.1 billion in the US, down 37% due to sales “strongly impacted” by the uptake of biosimilars, the company reported.
Meanwhile, Outlook Therapeutics is looking to bring a bevacizumab biosimilar, the active compound in Avastin, to market for ophthalmic indications. The company withdrew a BLA back in May for wet AMDAMD after the FDA requested additional information, then resubmitted last month.
Microcap's effort to take on Eylea with Avastin biosimilar faces significant FDA roadblock
Analysts at Cardinal Health called last year one of the “most eventful” in US biosimilars’ history, noting milestones such as Viatris’ Semglee as the first interchangeable biosimilar and the first OK for a biosimilar in ophthalmology, Biogen’s Byooviz.
Researchers say biosimilars are on track to reduce US drug expenditure by $133 billion by 2025. Momentum is “stronger than ever,” specialty solutions president Heidi Hunter told Endpoints News back in February, adding that this year could be a “turning point.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.